Bayer has continued to improve its operating performance. Business expansion has occurred in all Consumer Health divisions, especially in Consumer Care where products acquired by Merck & Co., Inc. have contributed. Significant growth in sales and earnings were reported at HealthCare.
The CropScience business were improved over the previous year quarter however overall earnings were down. Performance was steady even in a weaker market environment.
MaterialScience felt an expected slight decline in sales due to lower raw material prices resulting in lower selling prices.
Due to the positive business development seen in the first quarter this year Bayer will be raising their Group guidance for 2015 due to currency effects. Groups sales rose to EUR 12.1 billion. Net income decreased 8.4% to EUR 1.3 billion. EBITDA before special items increased 9.6% to EUR 3 billion and EBIT decreased 4.7% to EUR 2 billion. Core earnings per share raised 7.7% to EUR 2.10.
No comments:
Post a Comment